drugset / Trial / NCT00151996

Safety and Tolerability of SPD503 and Psychostimulants in Children and Adolescents Aged 6-17 With Attention-Deficit/Hyperactivity Disorder (ADHD)

NCT00151996

Phase 2 Completed 75 enrolled Shire
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the safety and tolerability of administering SPD503 (Guanfacine hydrochloride) with psychostimulants (amphetamine or methylphenidate) for treatment of ADHD in children and adolescents aged 6-17

Timeline

Start
2004-08-16
Primary completion
2004-12-27
Completion
2004-12-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Guanfacine Small molecule 1 mg
Subject Guanfacine Small molecule 2 mg
Subject Guanfacine Small molecule 3 mg
Subject Guanfacine Small molecule 4 mg
Background Amphetamine Unknown
Background Methylphenidate Small molecule